We’ve recently updated our valuation analysis.

Exagen Valuation

Is E08A undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for E08A?

Other financial metrics that can be useful for relative valuation.

E08A key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue0.4x
Enterprise Value/EBITDA-0.4x
PEG Ration/a

Price to Sales Ratio vs Peers

How does E08A's PS Ratio compare to its peers?

The above table shows the PS ratio for E08A vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average4.1x
PA8 Paion
1.3xn/a€41.6m
2INV 2invest
13.3xn/a€39.1m
MDG1 Medigene
1.4xn/a€42.2m
CNW co.don
0.7xn/a€6.5m
E08A Exagen
0.9x14.0%€43.0m

Price-To-Sales vs Peers: E08A is good value based on its Price-To-Sales Ratio (0.9x) compared to the peer average (4.1x).


Price to Earnings Ratio vs Industry

How does E08A's PE Ratio compare vs other companies in the European Biotechs Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a52.6%
n/an/an/a
No. of CompaniesPS048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a52.6%
n/an/an/a
No more companies

Price-To-Sales vs Industry: E08A is good value based on its Price-To-Sales Ratio (0.9x) compared to the European Biotechs industry average (9.6x)


Price to Sales Ratio vs Fair Ratio

What is E08A's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

E08A PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio0.9x
Fair PS Ratio2.5x

Price-To-Sales vs Fair Ratio: E08A is good value based on its Price-To-Sales Ratio (0.9x) compared to the estimated Fair Price-To-Sales Ratio (2.5x).


Share Price vs Fair Value

What is the Fair Price of E08A when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate E08A's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate E08A's fair value for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst E08A forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€2.28
€5.72
+150.8%
13.3%€6.40€4.57n/a4
Apr ’24€2.26
€5.75
+154.6%
13.3%€6.44€4.60n/a4
Mar ’24€2.38
€5.99
+151.5%
7.7%€6.45€5.53n/a4
Feb ’24€2.60
€5.99
+130.2%
7.7%€6.45€5.53n/a4
Jan ’24€2.24
€7.06
+215.3%
11.5%€8.48€6.59n/a4
Dec ’23€2.54
€7.21
+183.9%
11.5%€8.65€6.73n/a4
Nov ’23€2.58
€10.63
+311.9%
20.8%€14.17€8.10n/a4
Oct ’23€2.90
€12.29
+323.9%
18.6%€15.05€10.04n/a4
Sep ’23€4.44
€12.29
+176.9%
18.6%€15.05€10.04n/a4
Aug ’23€7.55
€15.76
+108.8%
11.9%€18.26€12.50n/a5
Jul ’23€5.40
€15.76
+191.9%
11.9%€18.26€12.50n/a5
Jun ’23€4.66
€15.76
+238.3%
11.9%€18.26€12.50n/a5
May ’23€5.95
€16.36
+175.0%
11.7%€18.18€13.64€2.305
Apr ’23€7.25
€16.36
+125.7%
11.7%€18.18€13.64€2.265
Mar ’23€6.75
€21.20
+214.1%
14.4%€26.28€17.52€2.385
Feb ’23€8.60
€21.20
+146.5%
14.4%€26.28€17.52€2.605
Jan ’23€9.70
€21.32
+119.8%
14.1%€26.21€17.47€2.245
Dec ’22€9.00
€21.32
+136.9%
14.1%€26.21€17.47€2.545
Nov ’22€9.95
€21.33
+114.4%
17.9%€28.16€17.07€2.585
Oct ’22€12.10
€21.33
+76.3%
17.9%€28.16€17.07€2.905
Sep ’22€11.80
€21.33
+80.8%
17.9%€28.16€17.07€4.445
Aug ’22€10.20
€22.14
+117.0%
13.5%€27.88€19.43€7.555
Jul ’22€12.60
€21.70
+72.2%
13.5%€27.33€19.05€5.405
Jun ’22€11.40
€21.70
+90.3%
13.5%€27.33€19.05€4.665
May ’22€14.10
€22.13
+57.0%
12.3%€27.46€19.97€5.955

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.


Discover undervalued companies